A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 389-398

  Elewski, B ^a   Pollak, R ^b   Ashton, S ^c   Rich, P ^d   Schlessinger, J ^e   Tavakkol, A ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Endeavor Clinical Trials PA   (United States)

^c Ashton Podiatry Associates PA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Aesthetica Day Spa   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; TERBINAFINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; LIVER FUNCTION TEST; MALE; MULTICENTER STUDY; MYCOLOGY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TOENAIL ONYCHOMYCOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; ONYCHOMYCOSIS; TABLETS; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 84856230680     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10660.x     Document Type: Article

References (36)

1. Alley MRK, Baker SJ, Beutner KR, et al. Recent progress on the topical therapy of onychomycosis. Exp Opin Invest Drugs 2007; 16: 157-67.
2. Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-8.
3. Burzykowski T, Molenberghs G, Abeck D, et al. High prevalence of foot diseases in Europe: results of the Achilles Project. Mycoses 2003; 46: 496-505.
4. Elewski BE,. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11: 415-29.
5. Katsambas A, Abeck D, Haneke E, et al. The effects of foot disease on quality of life: results of the Achilles Project. J Eur Acad Dermatol Venereol 2005; 19: 191-5.
6. Scher RK,. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996; 35: S2-5.
7. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702-4.
8. Elewski BE,. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36: 754-6.
9. Whittam LR, Hay RJ,. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87-9.
10. ® (terbinafine hydrochloride) tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp., 2005.
11. ® (itraconazole) capsules [prescribing information]. Titusville, NJ: Janssen Pharmaceutical Products, L.P., 2006.
12. Finch JJ, Warshaw EM,. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007; 20: 31-46.
13. ® nail lacquer (ciclopirox) topical solution, 8% [prescribing information]. Bridgewater, NJ: Dermik Laboratories, 2006.
14. Gupta AK, Fleckman P, Baran R,. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43: S70-80.
15. Gupta AK, Ryder JE, Lynch LE, et al. The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence. J Drugs Dermatol 2005; 4: 302-8.
16. Tavakkol A, Fellman S, Kianifard F,. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. Am J Geriatr Pharmacother 2006; 4: 1-13.
17. Jennings MB, Pollak R, Harkless LB, et al. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. J Am Podiatr Med Assoc 2006; 96: 465-73.
18. SP Europe. Noxafil 40 mg/ml oral suspension [summary of product characteristics]. Brussels, Belgium: SP Europe, 2010.
19. Schering Corporation. Noxafil® (posaconazole) oral suspension [prescribing information]. Kenilworth, NJ: Schering Corp., 2010.
20. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
21. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
22. Keating GM,. Posaconazole. Drugs 2005; 65: 1553-67.
23. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
24. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-403.
25. National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2006. Available at: (last accessed 25 October 2021).
26. Temple R,. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15: 241-3.
27. Gupta AK, Ryder JE, Chow M, et al. Dermatophytosis: the management of fungal infections. Skinmed 2005; 4: 305-10.
28. Gupta AK, Kohli Y, Batra R,. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol 2005; 43: 179-85.
29. Sigurgeirsson B, Billstein S, Rantanen T, et al. LION Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis. Br J Dermatol 1999; 141: 5-14.
30. Barchiesi F, Arzeni D, Camiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001; 39: 4208-9.
31. Correia O, Faergemann J, Nowicki R, et al. Clinical trial design-towards better practices. J Eur Acad Dermatol Venereol 2005; 19: 40-2.
32. Espinel-Ingroff A,. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-36.
33. BMJ Group. British National Formulary, Vol. 61. London: BMJ Group, 2011.
34. Tosti A, Piraccini BM, Lorenzi S,. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000; 42: 217-24.
35. Venkatakrishnan K, von Moltke LL, Greenblatt DJ,. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
36. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645-53.